Otsuka Pharmaceutical Co., Ltd.

This study is testing a new, once-daily capsule called EB-1020 to see if it can help control the core symptoms of ADHD in children and teenagers. It will compare two different doses of the medication against a placebo (a capsule with no active drug) over six weeks. The goal is to…

This study aims to check the long-term safety of a daily medication called EB-1020 for children and teenagers with ADHD. It will follow about 180 participants for 52 weeks to see how they tolerate the treatment. The main goal is to monitor for any side effects that may occur duri…

This study aims to see how safe and effective a new investigational drug called SEP-363856 is when taken for a full year by adults with stable schizophrenia. It will involve about 100 participants who will take the medication daily. The main goal is to monitor for any side effect…

This study is a survey to monitor the safety of the drug LUPKYNIS in 400 patients with lupus nephritis (kidney inflammation from lupus) under real-world conditions. It will collect information on any side effects, how the drug is used, and its effectiveness in everyday practice. …